Table 3.
Randomized Clinical Trials with Topical Lidocaine in Musculoskeletal Pain
| Authors | Population | Design* | Treatment | Sample Size | Maximum Dose/Nb of Plasters | Follow-Up Weeks | Concomitant Medication | Primary Outcome |
|---|---|---|---|---|---|---|---|---|
| Castro and Dent, 201767 | CLBP | Parallel | 5% Lidocaine plaster (Rx) vs 3.6% lidocaine plaster+1,25% menthol (OTC) vs placebo | NR | NR | NR | NR | Non-inferiority of OTC compared with Rx for efficacy, side effects and quality of life. Versus placebo, OTC proved superiority for efficacy, general activity and normal work |
| Hashmi et al, 201266 | CLBP | Parallel | 5% Lidocaine plaster vs placebo | 15 15 |
NR | 2 | NR | Pain intensity, sensory and affective qualities of pain or pain related brain activation at any time point (p=NS) |
| Kivitz et al, 200870 | OA | Parallel, open label, active-controlled | 5% Lidocaine plaster vs celecoxib 200mg | 69 74 |
1–1/3 | 12 | Yes | WOMAC OA subscale scores and mean rates of change over time (p=NS) |
Note: *All studies are randomized, double blind, crossover and versus (vs) placebo, unless specified.
Abbreviations: CLBP, chronic low back pain; OA, osteoarthritis pain; NR, not reported; No, no concomitant medication.